AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndromeAC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s DiseaseAC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
AC Immune to Present at the Jefferies 2024 London Healthcare ConferenceAC Immune to Present at the Jefferies 2024 London Healthcare Conference
AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate UpdateAC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s DiseaseAC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease
AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative ConditionsAC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions
AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate UpdateAC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024
AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s DiseaseAC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024
AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateAC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate UpdateAC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
AC Immune Announces Upcoming Presentations at AD/PD™ 2024AC Immune Announces Upcoming Presentations at AD/PD™ 2024
AC Immune to Regain Global Rights to Crenezumab and SemorinemabAC Immune to Regain Global Rights to Crenezumab and Semorinemab
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseasesAC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases
AC Immune Announces Pricing of Underwritten Offering of Common SharesAC Immune Announces Pricing of Underwritten Offering of Common Shares
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFOAC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO
AC Immune to Present at the Jefferies 2023 London Healthcare ConferenceAC Immune to Present at the Jefferies 2023 London Healthcare Conference
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate UpdateAC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023
AC Immune Announces Upcoming Presentations at the 16th CTAD ConferenceAC Immune Announces Upcoming Presentations at the 16th CTAD Conference
AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023
AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate UpdateAC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023
AC Immune SA Appoints New Chief Medical OfficerAC Immune SA Appoints New Chief Medical Officer
AC Immune Showcasing Precision Medicine Programs at AAIC 2023AC Immune Showcasing Precision Medicine Programs at AAIC 2023
AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s DiseaseAC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease
AC Immune Holds Annual General Meeting of ShareholdersAC Immune Holds Annual General Meeting of Shareholders
AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate UpdateAC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update
AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer’s DiseaseAC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer’s Disease
AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine PipelineAC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate UpdateAC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update
AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023
AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43
AC Immune to Present at the SVB Securities Global Biopharma ConferenceAC Immune to Present at the SVB Securities Global Biopharma Conference
AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE TrialAC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial
AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s DiseaseAC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease
AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further DevelopmentAC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development
AC Immune to Present Progress of Alzheimer’s Disease Programs targeting Abeta and Tau at the 15th CTAD ConferenceLausanne, Switzerland, November 23, 2022 – AC Immune SA (
NASDAQACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the upcoming presentations of its vaccine technology SupraAntigen®, and of its anti-Tau and anti-Abeta investigational candidates, at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference in San Francisco, California (United States) and online, on November 29 – December 2, 2022.
